Nienke Bollen
Managing Partner at Providence Capital NV
Amsterdam, North Holland
Nienke Bollen, Managing Partner at Providence Capital NV is an active investor based in Amsterdam, North Holland. This profile covers what Nienke Bollen backs, at which stage, and how founders can reach out in 2026.
- Investor type
- VC
- Stages
- SeedSeries A
- Invests in
- SaaS & Enterprise
- Location
- Amsterdam, North Holland
- Typical check
- $625K
How to reach Nienke Bollen
Angels and operators like Nienke Bollen reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Connect with Nienke Bollen
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise.
Frequently Asked Questions
What does Nienke Bollen invest in?
Nienke Bollen invests in SaaS & Enterprise, typically at Seed and Series A. Match your sector and stage, then reach out with a personalized pitch.
What stage does Nienke Bollen invest at?
Nienke Bollen typically invests at Seed and Series A. Lead with traction that fits the stage when you reach out.
What is Nienke Bollen's typical check size?
Nienke Bollen typically writes checks around $625K. Use it as a signal for whether your raise fits their stage.
How do I contact Nienke Bollen?
Unlock Nienke Bollen's verified email on Round Funded and send a personalized pitch. We surface only deliverable contacts so your outreach lands.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.